Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
The objective behind introducing this extraordinary digital campaign is to spread awareness among Gen X and Z for the need of breast self-examination
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Subscribe To Our Newsletter & Stay Updated
